Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapTem with Y90 Radioembolization in Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors
NCT04339036Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2021
- Primary completion
- Jul 2028
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, temozolomide, yttrium-90 in Neuroendocrine Neoplasm (NEN), sponsored by Abramson Cancer Center. Started Oct 2021; status: recruiting.
02
Drugs
capecitabinetemozolomideyttrium-90
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04339036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339036.